Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.

摘要: With the introduction of targeted agents primarily applicable to non-small cell lung cancer (NSCLC) adenocarcinoma histology, there is a heightened unmet need in squamous carcinoma population. Targeting angiogenic fibroblast growth factor (FGF)/FGF receptor (FGFR) signaling pathway among strategies being explored NSCLC; these efforts are supported by growth-promoting effects FGF preclinical studies (including interactions with other pathways) and observations suggesting that FGF/FGFR-related aberrations may be more common versus histologies. A number different anti-FGF/FGFR approaches have shown promise studies. Clinical trials two multitargeted tyrosine kinase inhibitors restricting enrollment patients NSCLC: phase I/II trial nintedanib added first-line gemcitabine/cisplatin II ponatinib for previously treated advanced disease, latter requiring not only disease but also confirmed FGFR amplification or mutation. There several ongoing clinical general NSCLC populations, including limited disease. Other FGF/FGFR-targeted earlier development. While results awaited from investigations settings, additional research needed elucidate role FGF/FGFR biology